Gyre Therapeutics (NASDAQ:GYRE) Downgraded to Strong Sell Rating by Zacks Research

Zacks Research downgraded shares of Gyre Therapeutics (NASDAQ:GYRE) from a hold rating to a strong sell rating in a research report report published on Tuesday,Zacks.com reports.

Several other research firms have also issued reports on GYRE. Wall Street Zen lowered shares of Gyre Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, May 16th. Weiss Ratings restated a “sell (d-)” rating on shares of Gyre Therapeutics in a report on Friday, August 7th. Two investment analysts have rated the stock with a Buy rating and two have given a Sell rating to the company’s stock. According to MarketBeat, the company has an average rating of “Hold” and an average price target of $17.00.

Gyre Therapeutics Trading Up 2.4%

Shares of Gyre Therapeutics stock opened at $7.15 on Tuesday. Gyre Therapeutics has a 52 week low of $5.44 and a 52 week high of $9.42. The stock has a market cap of $797.30 million, a PE ratio of -34.05 and a beta of 1.92. The company’s 50-day moving average price is $6.38 and its two-hundred day moving average price is $7.00.

Gyre Therapeutics (NASDAQ:GYRE) last announced its quarterly earnings data on Friday, August 7th. The company reported ($0.12) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.06) by ($0.06). Gyre Therapeutics had a negative return on equity of 6.57% and a negative net margin of 15.47%.The business had revenue of $29.11 million during the quarter, compared to analyst estimates of $26.49 million. On average, equities analysts predict that Gyre Therapeutics will post -0.61 EPS for the current fiscal year.

Institutional Investors Weigh In On Gyre Therapeutics

A number of hedge funds have recently added to or reduced their stakes in the stock. Bank of America Corp DE acquired a new position in shares of Gyre Therapeutics during the second quarter worth approximately $83,000. BlackRock Inc. acquired a new position in Gyre Therapeutics during the 2nd quarter worth $6,550,000. Deutsche Bank AG acquired a new position in Gyre Therapeutics during the 2nd quarter worth $118,000. Bank of New York Mellon Corp bought a new position in Gyre Therapeutics in the 2nd quarter valued at $414,000. Finally, Dimensional Fund Advisors LP increased its stake in shares of Gyre Therapeutics by 131.8% in the 1st quarter. Dimensional Fund Advisors LP now owns 25,268 shares of the company’s stock valued at $176,000 after buying an additional 14,365 shares during the period. Institutional investors own 23.99% of the company’s stock.

About Gyre Therapeutics

Gyre Therapeutics, Inc is a clinical-stage biotechnology company focused on discovering and developing small-molecule therapies that target lipid biology to treat a range of metabolic, inflammatory and neurodegenerative diseases. The company’s proprietary platform combines lipidomic profiling with drug discovery tools to identify compounds that selectively modulate membrane lipid composition and restore normal protein function in disease-relevant cells.

Gyre’s preclinical pipeline includes programs in nonalcoholic steatohepatitis (NASH), Alzheimer’s disease and autoimmune conditions, reflecting its strategy of applying a unified lipid-targeted approach across multiple therapeutic areas.